What occurred
In keeping with an SEC filing dated Might 15, 2026, Acuta Capital Companions, LLC initiated a brand new place in Erasca (NASDAQ:ERAS) through the first quarter. The fund acquired 354,575 shares, with an estimated transaction worth of $4.19 million primarily based on the common closing worth for the interval. The quarter-end worth of the stake rose to $5.74 million, a change reflecting each the share addition and worth fluctuations through the quarter.
What else to know
-
This was a brand new place for the fund, representing 4.05% of reported U.S. fairness holdings as of March 31, 2026
-
Prime holdings after the submitting:
-
NASDAQ: PRAX: $27.35 million (19.8% of AUM)
-
NASDAQ: TERN: $26.14 million (18.9% of AUM)
-
NASDAQ: WHWK: $11.77 million (8.5% of AUM)
-
NASDAQ: TNGX: $9.24 million (6.7% of AUM)
-
NASDAQ: DRUG: $8.17 million (5.9% of AUM)
-
-
As of Might 14, 2026, Erasca shares had been priced at $10.37, up 716.5% over the prior yr, delivering alpha of 689.24 share factors versus the S&P 500
Firm Overview
|
Metric |
Worth |
|---|---|
|
Worth (as of market shut 2026-05-15) |
$10.23 |
|
Market capitalization |
$3.15 billion |
|
Internet revenue (TTM) |
$-277.02 million |
|
One-year worth change |
705.5% |
Firm Snapshot
-
Develops and advances focused therapies for RAS/MAPK pathway-driven cancers, with lead medical candidates together with ERAS-007 (oral ERK1/2 inhibitor), ERAS-601 (oral SHP2 inhibitor), and ERAS-801 (CNS-penetrant EGFR inhibitor).
-
Operates as a clinical-stage biopharmaceutical firm centered on the event and future commercialization of proprietary oncology therapeutics.
-
Targets sufferers with difficult-to-treat cancers resembling non-small cell lung most cancers, colorectal most cancers, acute myeloid leukemia, and recurrent glioblastoma multiforme.
Erasca, Inc. is a biotechnology firm headquartered in San Diego, California, centered on discovering and growing therapies for cancers pushed by the RAS/MAPK pathway. The corporate leverages a sturdy pipeline of oral focused inhibitors, aiming to handle important unmet medical wants in oncology. Its technique facilities on advancing medical candidates with differentiated mechanisms of motion to ascertain a aggressive edge in focused most cancers therapeutics.
What this transaction means for traders
Acuta Capital’s new Erasca place isn’t within the agency’s prime 5, nevertheless it’s a major wager. It was the seventh largest place out of 27 on the finish of March.
Hopefully, Acuta Capital exited its place in April, earlier than the inventory collapsed. The inventory is down by greater than half from the height it set in April.
On April 27, the corporate reported part 1 trial outcomes for ERAS-0015, a most cancers remedy candidate it describes as pan-RAS molecular glue. The corporate’s experimental therapies are designed to close down the RAS/MAPK pathway, which is implicated within the spreading of stable tumors.
